
    
      This intermediate-size expanded access protocol plans to treat approximately 50 children or
      adolescents, male and female, with MIS-C associated with COVID-19. Participants who are 2
      months to 17 years of age, inclusive, will be enrolled at multiple clinical sites across the
      United States.
    
  